93 related articles for article (PubMed ID: 2417650)
1. DNA/RNA ratio in bladder cancer: a factor indicating the recurrence rate?
Hadjissotiriou GG; Green DK; McIntyre MA; Hargreave TB; Chisholm GD
Br J Urol; 1985 Dec; 57(6):668-75. PubMed ID: 2417650
[TBL] [Abstract][Full Text] [Related]
2. Mitomycin C in superficial bladder cancer: 24-month follow-up.
Somerville JJ; Newling DW; Richards B; Robinson MR; Smith PH
Br J Urol; 1985 Dec; 57(6):686-9. PubMed ID: 3936564
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of urine cytology on initial follow-up after intravesical mitomycin C for superficial bladder cancer.
Cant JD; Murphy WM; Soloway MS
Cancer; 1986 Jun; 57(11):2119-22. PubMed ID: 3084057
[TBL] [Abstract][Full Text] [Related]
4. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
5. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
[TBL] [Abstract][Full Text] [Related]
6. [Intravesical mitomycin for superficial tumors of the bladder: difficulties of cystoscopic monitoring].
Fourcade RO; Giuliano F
Ann Urol (Paris); 1988; 22(6):404-6. PubMed ID: 3146942
[TBL] [Abstract][Full Text] [Related]
7. Intravesical instillation of mitomycin-C in 242 patients with superficial bladder cancer at high risk of recurrence: long-term results.
Hurle R; Manzetti A; Losa A; Micheli E; Ranieri A; Chinaglia D; Lembo A
Urol Int; 1998; 61(4):220-6. PubMed ID: 10364753
[TBL] [Abstract][Full Text] [Related]
8. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial).
O'Brien T; Ray E; Singh R; Coker B; Beard R;
Eur Urol; 2011 Oct; 60(4):703-10. PubMed ID: 21684068
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
10. Superficial bladder tumours: recurrence and progression.
Mansoor M; Ali S; Fasihuddin Q; Baloch MU
J Coll Physicians Surg Pak; 2011 Mar; 21(3):157-60. PubMed ID: 21419022
[TBL] [Abstract][Full Text] [Related]
11. Long-term observation after intravesical metaphylaxis with mitomycin C in patients with superficial bladder tumors.
Maier U; Höbarth K
Urology; 1991 May; 37(5):481-2. PubMed ID: 1902606
[TBL] [Abstract][Full Text] [Related]
12. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).
Tolley DA; Hargreave TB; Smith PH; Williams JL; Grigor KM; Parmar MK; Freedman LS; Uscinska BM
Br Med J (Clin Res Ed); 1988 Jun; 296(6639):1759-61. PubMed ID: 3136828
[TBL] [Abstract][Full Text] [Related]
13. Single instillation of mitomycin C reduces 1st year recurrence following transurethral resection of non-muscle invasive bladder cancer.
Ather MH; Aziz S; Sulaiman MN
J Ayub Med Coll Abbottabad; 2007; 19(4):18-20. PubMed ID: 18693589
[TBL] [Abstract][Full Text] [Related]
14. Mitomycin C for the treatment of bladder cancer.
Volpe A; Racioppi M; D'Agostino D; Cappa E; Filianoti A; Bassi PF
Minerva Urol Nefrol; 2010 Jun; 62(2):133-44. PubMed ID: 20562793
[TBL] [Abstract][Full Text] [Related]
15. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
[TBL] [Abstract][Full Text] [Related]
16. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival.
Huland H; Otto U; Droese M; Klöppel G
J Urol; 1984 Jul; 132(1):27-9. PubMed ID: 6427483
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
18. Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor.
Kim HH; Lee C
J Urol; 1989 Jun; 141(6):1337-9; discussion 1339-40. PubMed ID: 2498532
[TBL] [Abstract][Full Text] [Related]
19. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.
Halachmi S; Moskovitz B; Maffezzini M; Conti G; Verweij F; Kedar D; Sandri SD; Nativ O; Colombo R
Urol Oncol; 2011; 29(3):259-64. PubMed ID: 19395285
[TBL] [Abstract][Full Text] [Related]
20. Intravesical mitomycin C for the treatment of recurrent superficial bladder tumours.
Hetherington JW; Newling DW; Robinson MR; Smith PH; Adib RS; Whelan P
Br J Urol; 1987 Mar; 59(3):239-41. PubMed ID: 3105631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
